Functional analysis of a novel breast cancer related protein: EphA10 for development of anti-EphA10 antibody drugs in refractory breast cancer cases
| Project/Area Number |
26430180
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Osaka University (2015-2016)
独立行政法人医薬基盤研究所 (2014) |
|---|
Principal Investigator |
NAGANO Kazuya 大阪大学, 薬学研究科, 准教授 (40548301)
|
|---|
| Research Collaborator |
TSUNODA Shin-ichi
KAMADA Haruhiko
MIYOSHI Jun
OKAMOTO Miki
NISHIZAWA Kyoko
MATSUDA Jun-ichiro
MUKAI Yohei
TSUTSUMI Yasuo
YOSHIOKA Yasuo
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | Eph receptor A10 / 抗体療法 / アカデミア創薬 |
|---|
| Outline of Final Research Achievements |
The purpose of this research is to reveal the EphA10 function in both breast cancer tissues and normal tissues, for development of an anti-EphA10 antibody drug in refractory breast cancer cases. The function analysis of EphA10 in breast cancer cells showed that EphA10 promoted breast cancer cell proliferation, suggesting that Clone: LBR inhibited tumor growth by CDC or neutralizing activity. On the other hand, the function analysis of EphA10 in testis tissues showed that EphA10 might inhibit the tissue growth and testosterone secretion. Furthermore, we could successfully isolate human anti-EphA10 monoclonal antibody candidates for clinical trials. Consequently, we hope that the findings contribute to the development of effective and safe antibody drugs.
|
Report
(4 results)
Research Products
(19 results)
-
-
-
-
-
-
[Journal Article] Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers.2014
Author(s)
Kazuya Nagano, Yuka Maeda, So-ichiro Kanasaki, Takanobu Watanabe, Takuya Yamashita, Masaki Inoue, Kazuma Higashisaka, Yasuo Yoshioka, Yasuhiro Abe, Yohei Mukai, Haruhiko Kamada, Yasuo Tsutsumi, Shin-ichi Tsunoda.
-
Journal Title
Journal of Controlled Release
Volume: 189
Pages: 72-79
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
-
-
[Presentation] 乳がん関連たんぱく質EphA10の各種がんでの発現分布の解析2016
Author(s)
長野一也, 森 宣瑛, 永野貴士, 向井美穂, 大須賀絵理, 竹谷苑子, 芳賀優弥, 井阪 亮, 鎌田春彦, 角田慎一, 堤 康央
Organizer
日本薬学会第136年会
Place of Presentation
パシフィコ横浜（横浜・神奈川）
Year and Date
2016-03-26
Related Report
-
-
-
-
-
[Presentation] Development and evaluation of a monoclonal antibody against Eph receptor A10 for novel molecular targeted therapy of breast cancers2015
Author(s)
Kazuya Nagano, Yuka Maeda, Takuya Yamashita, Masaki Inoue, Yohei Mukai, Haruhiko Kamada, Kazuma Higashisaka, Yasuo Yoshioka, Yasuo Tsutsumi, Shin-ichi Tsunoda
Organizer
Controlled Release Society Annual Meeting 2015
Place of Presentation
Edinburgh International Conference Centre (Edinburgh, Scotland)
Year and Date
2015-07-26
Related Report
Int'l Joint Research
-
-
-
-
